Behind the Science: Behind Prescribing SGLT-2 Inhibitors

The notable history of the sodium-glucose cotransporter-2 (SGLT2) inhibitor class of drugs began with approval in 2014 as a treatment for type 2 diabetes. Since then, they have been approved by the FDA for treating or reducing risk of a spectrum of cardiovascular and renal disease, regardless of diabetes status. Specialists and a primary care clinician answered the question: Who should prescribe these drugs, specialists or primary care clinicians?